Prima Biomed (ASX:PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac(tm) has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.
Prima Biomed Ltd
ASX:PRR ISIN:AU000000PRR9
ข่าว
###
139,184 เข้าดูประวัติของบริษัท
- หน้านี้ถูกเปิดดู: (7 วันล่าสุด: 12) (ช่วง 30 วันที่: 56) (นับตั้งแต่ที่เผยแพร่: 10673)